Eli Lilly and Company (NYSE:LLY) Position Raised by Terra Nova Asset Management LLC

Terra Nova Asset Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,146 shares of the company’s stock after purchasing an additional 251 shares during the quarter. Eli Lilly and Company comprises 2.6% of Terra Nova Asset Management LLC’s portfolio, making the stock its 7th largest position. Terra Nova Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,000,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. State Street Corp raised its position in Eli Lilly and Company by 1.9% in the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after acquiring an additional 642,274 shares during the period. Morgan Stanley raised its position in Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares during the period. Northern Trust Corp raised its position in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares during the period. Finally, Norges Bank bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $3,416,206,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.0 %

NYSE:LLY opened at $777.96 on Friday. The company has a market cap of $739.19 billion, a PE ratio of 134.13, a P/E/G ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $334.58 and a twelve month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company’s 50 day moving average is $730.97 and its two-hundred day moving average is $637.01.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.09 EPS. Analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Barclays raised their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Finally, Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $689.52.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold 195,055 shares of company stock valued at $125,254,657 in the last ninety days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.